세계의 핵산 증폭 검사(NAAT) 시장 : 시장 규모 조사 - 유형별, 용도별, 최종 용도별, 지역별 예측(2022-2032년)

The Global Nucleic Acid Amplification Testing Market is valued at approximately USD 8.19 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.2% over the forecast period 2024-2032. Nucleic Acid Amplification Testing (NAAT) is a molecular technique used to detect and amplify specific nucleic acid sequences, such as DNA or RNA, from pathogens or genetic material. This method includes PCR (Polymerase Chain Reaction), RT-PCR (Reverse Transcription PCR), and LAMP (Loop-Mediated Isothermal Amplification). NAAT is highly sensitive and specific, making it valuable for diagnosing infectious diseases like COVID-19, tuberculosis, and HIV. It is also used in genetic testing, cancer detection, and forensic science. NAAT enables early and accurate detection of diseases, guiding appropriate treatment and management strategies.

The market's growth is fueled by a surge in demand for advanced rapid diagnostics and rising R&D investments in developing novel biotechnological diagnostic techniques. The high global prevalence of infectious diseases and the need for highly efficient testing alternatives to successfully manage disease outbreaks have propelled the demand for various nucleic acid amplification testing technologies. COVID-19, in particular, has significantly increased the demand for rapid and accurate testing methods to detect the SARS-CoV-2 virus. Key market players have responded by developing new product offerings, such as isothermal nucleic acid amplification technology-based tests, to meet the high demand for rapid and point-of-care testing.

The major factors driving the NAAT market include the rising prevalence of infectious diseases, increasing demand for advanced diagnostic measures, and growing investment in developing new biotechnological diagnostic techniques. However, a lack of skilled professionals and the higher costs associated with these tests may restrain the market's growth. Nonetheless, the global increase in healthcare spending and continuous advancements in diagnostic technology provide significant growth opportunities for the NAAT market.

North America dominated the market in 2023, accounting for the largest revenue share due to the high prevalence of chronic diseases and the presence of an established research and healthcare infrastructure. The demand for nucleic acid amplification tests in the region is driven by the increasing focus on point-of-care diagnostic methods and extensive disease prevention measures. In contrast, the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, driven by its large population and rising focus on healthcare systems. The high incidence of emerging infectious diseases such as Japanese encephalitis, Hendra, and Nipah virus infections can strengthen the market prospects for nucleic acid amplification testing in the region.

Major market players included in this report are:

• F. Hoffmann-La Roche Ltd
• Becton, Dickinson and Company
• Danaher Corporation
• Abbott Laboratories
• Illumina, Inc.
• Siemens Healthineers
• bioMerieux SA
• Novartis AG
• Bio-Rad Laboratories, Inc.
• Seegene Inc.

The detailed segments and sub-segment of the market are explained below:

By Type:

• Polymerase Chain Reaction (PCR) Tests
• Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
• Ligase Chain Reaction (LCR) Tests

By Application:

• Infectious Disease Testing
• Oncology Testing
• Genetic & Mitochondrial Disease Testing
• Others

By End-use:

• Hospitals
• Central And Reference Laboratories
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Nucleic Acid Amplification Testing Market Executive Summary

• 1.1. Global Nucleic Acid Amplification Testing Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Type
  • 1.3.2. By Application
  • 1.3.3. By End-use
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Nucleic Acid Amplification Testing Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Nucleic Acid Amplification Testing Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Increasing Prevalence of Infectious Diseases
  • 3.1.2. Rising Investment in Biotechnological Diagnostics
  • 3.1.3. Technological Advancements in Diagnostic Methods
• 3.2. Market Challenges
  • 3.2.1. Lack of Skilled Professionals
  • 3.2.2. High Costs Associated with NAAT
• 3.3. Market Opportunities
  • 3.3.1. Expansion in Emerging Markets
  • 3.3.2. Growth in Point-of-Care Diagnostics
  • 3.3.3. Increasing R&D Investments

Chapter 4. Global Nucleic Acid Amplification Testing Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Nucleic Acid Amplification Testing Market Size & Forecasts by Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Nucleic Acid Amplification Testing Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Polymerase Chain Reaction (PCR) Tests
  • 5.2.2. Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
  • 5.2.3. Ligase Chain Reaction (LCR) Tests

Chapter 6. Global Nucleic Acid Amplification Testing Market Size & Forecasts by Application 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Nucleic Acid Amplification Testing Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Infectious Disease Testing
  • 6.2.2. Oncology Testing
  • 6.2.3. Genetic & Mitochondrial Disease Testing
  • 6.2.4. Others

Chapter 7. Global Nucleic Acid Amplification Testing Market Size & Forecasts by End-use 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Nucleic Acid Amplification Testing Market: End-use Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Hospitals
  • 7.2.2. Central And Reference Laboratories
  • 7.2.3. Others

Chapter 8. Global Nucleic Acid Amplification Testing Market Size & Forecasts by Region 2022-2032

• 8.1. North America Nucleic Acid Amplification Testing Market
  • 8.1.1. U.S. Nucleic Acid Amplification Testing Market
    • 8.1.1.1. Type breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Application breakdown size & forecasts, 2022-2032
    • 8.1.1.3. End-use breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Nucleic Acid Amplification Testing Market
• 8.2. Europe Nucleic Acid Amplification Testing Market
  • 8.2.1. U.K. Nucleic Acid Amplification Testing Market
  • 8.2.2. Germany Nucleic Acid Amplification Testing Market
  • 8.2.3. France Nucleic Acid Amplification Testing Market
  • 8.2.4. Spain Nucleic Acid Amplification Testing Market
  • 8.2.5. Italy Nucleic Acid Amplification Testing Market
  • 8.2.6. Rest of Europe Nucleic Acid Amplification Testing Market
• 8.3. Asia-Pacific Nucleic Acid Amplification Testing Market
  • 8.3.1. China Nucleic Acid Amplification Testing Market
  • 8.3.2. India Nucleic Acid Amplification Testing Market
  • 8.3.3. Japan Nucleic Acid Amplification Testing Market
  • 8.3.4. Australia Nucleic Acid Amplification Testing Market
  • 8.3.5. South Korea Nucleic Acid Amplification Testing Market
  • 8.3.6. Rest of Asia Pacific Nucleic Acid Amplification Testing Market
• 8.4. Latin America Nucleic Acid Amplification Testing Market
  • 8.4.1. Brazil Nucleic Acid Amplification Testing Market
  • 8.4.2. Mexico Nucleic Acid Amplification Testing Market
  • 8.4.3. Rest of Latin America Nucleic Acid Amplification Testing Market
• 8.5. Middle East & Africa Nucleic Acid Amplification Testing Market
  • 8.5.1. Saudi Arabia Nucleic Acid Amplification Testing Market
  • 8.5.2. South Africa Nucleic Acid Amplification Testing Market
  • 8.5.3. Rest of Middle East & Africa Nucleic Acid Amplification Testing Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. F. Hoffmann-La Roche Ltd
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Becton, Dickinson and Company
  • 9.3.3. Danaher Corporation
  • 9.3.4. Abbott Laboratories
  • 9.3.5. Illumina, Inc.
  • 9.3.6. Siemens Healthineers
  • 9.3.7. bioMerieux SA
  • 9.3.8. Novartis AG
  • 9.3.9. Bio-Rad Laboratories, Inc.
  • 9.3.10. Seegene Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes